

### AMENDMENTS TO THE CLAIMS

Claim 1 (Previously presented): ~~An isolated human antibody that specifically binds to an epitope specifically bound by an antibody expressed by clone huC25, , wherein said antibody binds to and neutralizes~~ botulinum neurotoxin type A (BoNT/A), wherein said antibody comprises a heavy variable domain (VH) comprising complementarity determining regions having the amino acid sequence of VH CDR1 (SEQ ID NO:87), VH CDR2 (SEQ ID NO:89), and VH CDR3 (SEQ ID NO:127).

Claims 2-16 (Canceled).

Claim 17 (Currently amended): An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody comprises a light variable domain (VL) comprising complementarity determining regions having the amino acid sequence of VL CDR1 (SEQ ID NO:157), VL CDR2 (SEQ ID NO:159), and VL CDR3 (SEQ ID NO:197). ~~The antibody of claim 1, wherein said antibody comprises at least two variable heavy (V<sub>H</sub>) complementarity determining regions (CDRs) of huC25.~~

Claim 18 (Currently amended): An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody further comprises a heavy variable domain (VH) comprising complementarity determining regions having the amino acid sequence of VH CDR1 (SEQ ID NO:87), VH CDR2 (SEQ ID NO:89), and VH CDR3 (SEQ ID NO:127); and a light variable domain (VL) comprising complementarity determining regions having the amino acid sequence of VL CDR1 (SEQ ID NO:157), VL CDR2 (SEQ ID NO:159), and VL CDR3 (SEQ ID NO:197). ~~The antibody of claim 17, wherein said antibody comprises at three variable heavy (V<sub>H</sub>) complementarity determining regions (CDRs) of HuC25.~~

Claims 19-22.

Claim 23 (Currently amended): The antibody of any one of claims 1, 17, or 18, ~~claim 1,~~ wherein said antibody is a single chain Fv (scFv).

Claim 24 (Currently amended): The antibody of any one of claims 1, 17, or 18, ~~claim 1,~~ wherein said antibody is an IgG.

Claim 25 (Currently amended): The antibody of any one of claims 1, 17, or 18, ~~claim 1,~~ wherein said antibody is a Fab.

Claim 26 (Currently amended): The antibody of any one of claims 1, 17, or 18, ~~claim 1,~~ wherein said antibody is a (Fab')<sub>2</sub>.

Claim 27 (Currently amended): The antibody of any one of claims 1, 17, or 18, ~~claim 1,~~ wherein said antibody is a (scFv')<sub>2</sub>.

Claim 28 (Original): The antibody of claim 27, wherein said antibody is a fusion protein of two scFv fragments.

Claim 29 (Currently amended): The antibody of claim 1, wherein said antibody comprises a the heavy variable framework region of huC25.

Claim 30 (Currently amended): The antibody of claim ~~29~~17, wherein said antibody comprises the light variable framework region ~~framework is a variable heavy (V<sub>H</sub>) framework~~ of huC25.

Claim 31 (Currently amended): The antibody of claim 1, wherein said antibody comprises a variable heavy region of huC25.~~29, wherein said framework is a variable light (V<sub>L</sub>) framework of huC25.~~

Claim 32 (Currently amended): The antibody of claim 17, wherein said antibody comprises the variable light region of huC25.~~30, wherein said antibody comprises at least two variable heavy (V<sub>H</sub>) framework regions of huC25.~~

Claim 33 (Currently amended): The antibody of claim 18, wherein said antibody comprises the variable heavy region of huC25 and the variable light region of huC25.~~31, wherein said antibody comprises at least two variable light (V<sub>L</sub>) framework regions of huC25.~~

Claims 34 (Currently amended): The antibody of claim 18, wherein said antibody comprises the amino acid sequence of huC25 scFv, ~~30, wherein said antibody comprises a variable heavy (V<sub>H</sub>) region of huC25.~~

Claims 35-115 (Canceled).

Claim 116 (Currently amended): A composition comprising a plurality of anti-botulinum neurotoxin antibodies, wherein each species of antibody is specific for a different epitope of a botulinum neurotoxin, and wherein said combination of antibodies shows greater toxin neutralization than the single antibodies comprising said plurality, and wherein said composition comprises an antibody according to any one of claims 1, 17, or 18.

Claim 117 (Original): The composition of claim 116, wherein said composition comprises a first antibody that binds and neutralizes an A1 toxin and a second antibody that binds and neutralizes an A2 toxin.

Claim 118 (Canceled).